← Eichor
Condition: Participants With Mild Hepatic Impairment Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Participants With Mild Hepatic Impairment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Partici
Phase 1 · 8 location(s) · Eisai Co., Ltd. · NCT04271488A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants
Phase 1 · 3 location(s) · Bristol-Myers Squibb · NCT07248839A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Modera
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07165002A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healt
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07401862A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Phase 1 · 3 location(s) · Boehringer Ingelheim · NCT07023354A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets i
Phase 1 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT07694843To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
Phase 1 · 2 location(s) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · NCT07480824
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.